Informed method of choice concerning conservative therapy of BPH
DOI: 10.32364/2587-6821-2022-6-4-187-194
N.A. Nashivochnikova
Privolzhsky Research Medical University, Nizhny Novgorod, Russian Federation
The follow-up results, as well as own case study, are presented to evaluate the efficacy and tolerability of creeping palm fruit extract (Permixon) in combination with an α-blocker in patients with lower urinary tract symptoms (LUTS) of moderate severity associated with benign prostatic hyperplasia (BPH). The follow-up study involved 58 male patients aged 48 to 70 years (mean age 60.1±3.4 years). Group 1 (n=30) was assigned a combined therapy with Tamsulosin (alpha blocker) (0.4 mg once daily) and Permixon (1 capsule, 160 mg, twice daily) for 6 months. Group 2 (n=28) underwent monotherapy with Tamsulosin (0.4 mg once daily) also for 6 months. The observed patients underwent a comprehensive urological examination, which included an assessment of symptoms in points on IPSS (International Prostate Symptom Score); laboratory and instrumental studies. The patients were examined before and 3 and 6 months after therapy initiation. Therapy tolerability was assessed by the frequency and severity of local and/or systemic adverse events. Initially, the maximum urinary flow rate, residual urine volume, IPSS and prostate volume in patients from both groups d id not differ statistically significantly. In the intergroup comparison, by 6 months of treatment (versus the treatment initiation), the average urinary flow rates in group 1 increased almost twice, and in group 2 only by 18% (p<0.05). There was a decrease in the residual urine volume in patients of groups 1 and 2, respectively, by 52.6 and 22.6% (p<0.05). The sum of the IPSS decreased by 46.1 and 21.5%, respectively (p<0.05). At the same time, no significant tendency in the volume of the prostate gland in group 2 were revealed in the first 3 months of therapy, However, after 6 months there was an increase in the average prostate volume by 8.8%. In group 1, prostate volume decreased by almost 20% over 6 months of therapy. The tolerability of the studied drug was satisfactory; no adverse events were noted in any patient. Permixone is an effective drug with a high safety profile within the pathogenetic therapy of BPH, affecting a number of factors concerning the development and progre ssion of this disease.
Keywords: benign prostatic hyperplasia, lower urinary tract symptoms, microcirculation, Serenoa repens, phytotherapy, Laser Doppler flowmetry.
For citation: Nashivochnikova N.A. Informed method of choice concerning conservative therapy of BPH. Russian Medical Inquiry. 2022;6(4):187–194 (in Russ.). DOI: 10.32364/2587-6821-2022-6-4-187-194.
2. Korneyev I.A., Alexeeva T.A., Al-Shukri S.H., Pushkar D.Yu. Lower urinary tract symptoms in male population of the Russian Federation north-western region: analysis of population study results. Urologicheskie vedomosti. 2016;6(1):5–9 (in Russ.). DOI: 10.17816/uroved615-9.
3. Ershov E.V. Evaluation of prostate blood circulation in patients with chronic prostatitis. Nephrology (Saint-Petersburg). 2007;11(1):103–107 (in Russ.).
4. Vasil’yev A.Yu., Gromov A.I. Color Doppler mapping using power Doppler in the assessment of prostate pathology. Voyenno-meditsinskiy zhurnal. 1997;318(4):33–37 (in Russ.).
5. Yesilevskiy Yu.M. Rheography of the organs of the genitourinary system. M.: Medpress-Inform; 2004 (in Russ.).
6. Vishnevskiy E.L. Clinical significance of functional research methods in diagnosing infravesical obstruction in children: thesis. М., 1973 (in Russ.).
7. Loran O.B., Vishnevskiy Ye.L., Vishnevskiy A.Ye. Treatment of urination disorders in patients with benign prostatic hyperplasia with a-blockers. M., 1998 (in Russ.).
8. Molochkov V.A., Il’in I.I. Chronic urethrogenic prostatitis. M.: Meditsina; 1998 (in Russ.).
9. Ryabinskiy B.C., Chechenin M.G. Place of transurethral electroresection in surgical treatment of patients with prostate adenoma. In: Material of the 8th All-Russian Congress of Urologists. Sverdlovsk, 1988:283–284 (in Russ.).
10. Tiktinskiy O.L. Surgical treatment of prostate adenoma and postoperative complications. In: Materials of the 8th All-Russian Congress of Urologists. Sverdlovsk, 1988:229–236 (in Russ.).
11. Tiktinskiy O.L., Mikhaylichenko V.V. Andrology. SPb.: Medis Press, 1999 (in Russ.).
12. Alyayev Yu.G., Vinarov A.Z. Alpha-blockers in the treatment of benign prostatic hyperplasia: present and prospects. Urologiya. 2000;1:2–10 (in Russ.).
13. Rasner P.I., Pushkar’ D.Yu. Management of lower urinary tract symptoms in patients with benign prostatic hyperplasia: current international standards. RMJ. 2016. (Electronic resource.) URL: https://www.rmj.ru/articles/urologiya/lechenie-simptomov-nizhnikh-mochevykh-putey-u-patsientov-s-dobrokachestvennoy-giperplaziey-predstate/ (access date: 12.02.2022) (in Russ.).
14. Russian clinical guidelines. Benign prostatic hyperplasia. 2020 (in Russ.).
15. Sivkov A.V. Diagnosis and treatment of benign prostatic hyperplasia. Consilium Medicum. 2003;5(1):9–18 (in Russ.).
16. Veliyev Ye.I., Okhrits V.Ye. 5-alpha-reductase inhibitors in modern urological practice. Effektivnaya farmakoterapiya. 2011;4:10–17 (in Russ.).
17. Abrams P., Kaplan S., De Koning Gans H.J., Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175(3 Pt 1):999–1004; discussion 1004. DOI: 10.1016/S0022-5347(05)00483-0.
18. Herschorn S., Jones J.S., Oelke M. et al. Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. Urology. 2010;75(5):1149–1155. DOI: 10.1016/j.urology.2009.09.007.
19. Novara G., Giannarini G., Alcaraz A. et al. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized. Controlled Trials. Eur Urol Focus. 2016;2(5):553–561. DOI: 10.1016/j.euf.2016.04.002.
20. Vela-Navarrete R., Alcaraz A., Rodríguez-Antolín A. et al. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon(®) ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int. 2018;122(6):1049–1065. DOI: 10.1111/bju.14362.
21. American Urological Association guidelines. 2020.
22. Kasyan G.R., Konovalov I.V. Current opportunities for combination treatment of lower urinary tract symptoms due to benign prostatic hyperplasia in men. Issled. prakt. Med. 2016;3(2):37–44 (in Russ.). DOI: 10.17709/2409-2231-2016-3-2-5.
23. Zitoun O.A., Farhat A.M., Mohamed M.A. et al. Management of benign prostate hyperplasia (BPH) by combinatorial approach using alpha1-adrenergic antagonists and 5-alpha-reductase inhibitors. Eur J Pharmacol. 2020;883:173301. DOI: 10.1016/j.ejphar.2020. 173301.
24. Van Asseldonk B., Barkin J., Elterman D.S. Medical therapy for benign prostatic hyperplasia: a review. Can J Urol. 2015;22 Suppl 1:7–17. PMID: 26497339.
25. Allkanjari O., Vitalone A. What do we know about phytotherapy of benign prostatic hyperplasia? Life Sci. 2015;126:42–56. DOI: 10.1016/j.lfs.2015.01.023.
26. Krivoborodov G., Tur E. Herbal therapy for patients with benign prostatic hyperplasia and chronic prostatitis. Medical Council. 2014;19:62–63 (in Russ.). DOI: 10.21518/2079-701X-2014-19-62-63.
27. Ullah R., Wazir J., Hossain M.A. et al. A glimpse into the efficacy of alternative therapies in the management of benign prostatic hyperplasia. Wien Klin Wochenschr. 2021;133(3–4):153–162. DOI: 10.1007/s00508-020-01692-z.
28. De la Taille A., Chalret du Rieu Q., Bardin L. Alpha-bloquants ou Permixon® pendant 6 mois: résultats d’une sous-population de l’étude PERSAT. Progrèsen Urologie. 2021;31(13):773. DOI: 10.1016/j.purol.2021.08.044.
29. Habib F.K., Ross M., Ho C.K. et al. Serenoa repens (Permixon) inhibits the 5 alpha-reductase activity of human prostate cancer cell lines without interfereng with PSA expression. Int J Cancer. 2005;114(2):190–194. DOI: 10.1002/ijc.20701.
30. Raynard J.P., Cousse H., Martin P.M. Inhibition of type 1 and type 2 5 alpha-reductase activity by free fatty acids, active ingredients of Permixon®. J Steroid Biochem Mol Biol. 2002;82(2–3):233–239. DOI: 10.1016/s0960-0760(02)00187-5.
31. Scaglione F., Luchini V., Pannacci M. et al. Comparison of the potency of different brands of Serenoa repens extract on 5alpha-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells. Pharmacology. 2008;82(4):270–275. DOI: 10.1159/000161128.
32. Rhodes L., Primka R.L., Berman C. et al. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate. 1993;22(1):43–51. DOI: 10.1002/pros.2990220107.
33. Scaglione F., Lucini V., Pannacci M. et al. Comparison of the potency of 10 different brands of Serenoa repens extracts. Eur Rev Med Pharmacol Sci. 2012;16(5):569–574. PMID: 22774395.
34. Koch E. Pharmakologie und Wirkmechanismen von Extrakten aus Sabalfructen (Sabal fructus), Brenneeelwurzen (Urticae radix und Kurbissamen (Cucurbitae peponis semen) bei der Behandlung der benignen Prostatahyperplasie. In: Loew D., Rietbrock N., eds. Phytopharmaka in Forschung und klinischer Anwendung. Darmstad: Steinkopff; 1995:57–59 (in German). DOI: 10.1007/978-3-642-85434-7_5.
35. Kuzmin I.V., Al-Shukri S.H. Prostagut-forte in benign prostate hyperplasia therapy: is pathogenic approach? Urologicheskiye vedomosti. 2012;2(3):18–23 (in Russ.).
36. Aboyan I.A., Tolmachev A.N., Lemeshko S.I. Morphological features of hyperplastic prostate tissue in patients with chronic prostatitis. Experimental and Clinical Urology. 2020;13(4):82–88 (in Russ.). DOI: 10.29188/2222-8543-2020-13-4-82-88.
37. De la Taille A. Therapeutic Approach: The Importance of Controlling Prostatic Inflammation. European Urology Supplements. 2013;12(5):116–122. DOI: 10.1016/j.eursup.2013.08.003.
38. Nashivochnikova N.A., Krupin V.N., Klochai V.V. Microcirculation of the bladder neck in patients with BPH. Meditsinskiy vestnik Bashkortostana. 2011;2:267–271 (in Russ.).
39. Carraro J.C., Raynaud J.P., Koch G. et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate. 1996;29(4):231–240; discussion 241–242. DOI: 10.1002/(SICI)1097-0045(199610)29:4<231::AID-PROS4>3.0.CO;2-E.
40. Debruyne F., Koch G., Boyle P. et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol. 2002;41(5):497–506; discussion 506–507. PMID: 12074791.
41. Glemain P., Coulange C., Billebaud T. et al. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial. Prog Urol. 2002;12(3):395–403; discussion 404. PMID: 12189745.
42. Ryu Y.W., Lim S.W., Kim J.H. et al. Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urol Int. 2015;94(2):187–193. DOI: 10.1159/000366521.
43. Instruction for medical use of the drug Permixon LP No.(000340)-(RG-RU)-300821.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
